WO2014077279A1 - Xkr8の機能を調節する物質のスクリーニング方法 - Google Patents
Xkr8の機能を調節する物質のスクリーニング方法 Download PDFInfo
- Publication number
- WO2014077279A1 WO2014077279A1 PCT/JP2013/080692 JP2013080692W WO2014077279A1 WO 2014077279 A1 WO2014077279 A1 WO 2014077279A1 JP 2013080692 W JP2013080692 W JP 2013080692W WO 2014077279 A1 WO2014077279 A1 WO 2014077279A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- xkr8
- cells
- cell
- membrane
- substances
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/04—Phospholipids, i.e. phosphoglycerides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Definitions
- the present invention relates to a screening method for substances that regulate the function of Xkr8.
- the phospholipids constituting the cell membrane are asymmetrically distributed in the outer and inner leaves.
- Phosphatidylserine (PtdSer) and phosphatidylethanolamine (PtdEtn) are present in the inner leaf of the cell membrane, and phosphatidylcholine (PtdCho) and sphingomyelin (SM) are mainly present in the outer leaf.
- PtdSer and PtdEtn in the cell membrane is maintained in an ATP-dependent manner by aminophospholipid translocase.
- the asymmetric distribution of phospholipids is destroyed by various biological processes, and cell surface PtdSer functions as a signal molecule.
- PtdSer exposed on the surface of apoptotic cells functions as an “eat me” signal for macrophages.
- PtdSer exposed on the cell surface activates blood coagulation factors and induces blood coagulation.
- TMEM16F was identified as a Ca 2+ -dependent phospholipid scrambrase as a molecule involved in phosphatidylserine exposure in activated platelets.
- TMEM16F-deficient cells exposed phosphatidylserine in the same manner as wild-type cells to stimulate apoptosis, it was thought that TMEM16F was not involved in the exposure of phosphatidylserine during apoptosis.
- the inventors of the present invention after intensive research, identified Xkr8 as a protein involved in PtdSer exposure during apoptosis and completed the present invention.
- the present invention provides the following: A method for screening a substance that regulates the function of Xkr8, comprising the following steps: (1) contacting Xkr8-expressing cells with a candidate substance for a substance that regulates the function of Xkr8; and (2) selecting a candidate substance that changes the distribution of phospholipids in the cell membrane of the cell.
- the present invention provides a screening method for substances that regulate the function of Xkr8.
- Xkr8 Molecular cloning and characterization of Xkr8 (a). Ba / F3 stained with Cy5-Annexin IV and its sub-line LD-PS5-2-2 cells. Molecular cloning and characterization of Xkr8 (b). WR-Fas and its mXkr8-GFP or mTMEM16F-GFP expression transformant treated with FasL and stained with Cy5-Annexin IV. The photo below shows the cell lysate analyzed with anti-caspase 3 antibody and anti- ⁇ -tubulin antibody. Molecular cloning and characterization of Xkr8 (c).
- Non-expression of Xkr8 in PLB-985 cells or Raji cells (a). Jurkat, Namalwa, PLB-985, and Raji cells were treated with staurosporine (STS), UV, or FasL and stained with Cy5-Annexin V. Non-expression of Xkr8 in PLB-985 cells or Raji cells (b). Xkr8 mRNA levels in Jurkat, Namalwa, PLB-985, and Raji cells determined by real-time RT-PCR. Non-expression of Xkr8 in PLB-985 cells or Raji cells (c).
- NBD-PC incorporating the fluorescence intensity in the SytoxBlue negative fraction is shown in arbitrary units (arbitrary units). Characterization of scrambling activity by hXkr8 (d). Cells were incubated with NBD-SM as in FIG. 4c. Activation of Xkr8 by caspase to induce apoptotic PtdSer exposure (a). Amino acid sequence of Xkr8 of various species. The estimated transmembrane region is shown in gray. The caspase recognition site is boxed and the dibasic or diaromatic ER translocation signal is double underlined.
- Activation of Xkr8 by caspase to induce apoptotic PtdSer exposure (b). The structure of Xkr8. Activation of Xkr8 by caspase to induce apoptotic PtdSer exposure (c). Wild-type, caspase-resistant cocoon (2DA) and truncated cocoon (D) GFP fusions hXkr8 and mXkr8. TM, transcapsular region; RR / FF, putative dibasic or diaromatic sequences for ER emission. Activation of Xkr8 by caspase to induce apoptotic PtdSer exposure (d).
- PLB-985 cells and their GFP-expressing transformants and wild-type or mutant hXkr8 fusion protein-expressing transformants were exposed to STS and stained with Cy5-Annexin IV (d).
- Activation of Xkr8 by caspase to induce apoptotic PtdSer exposure (e).
- the cell lysate of FIG. 5d was analyzed with anti-GFP and anti-ICAD.
- WR-Fas and its GFP, mXkr8-GFP, or mXkr8 2DA-GFP expressing transformants were treated with FasL.
- 293T cell transformants expressing hXkr8-GFP or hXkr8D-GFP were observed with a fluorescence microscope. Scale bar, 10 ⁇ m.
- Establishment of mouse Xkr8 ⁇ / ⁇ fetal thymocytes (a). Xkr8 mRNA levels in the mouse tissues shown in the figure were measured by RT-PCR and shown as a comparison with Gapdh mRNA.
- Establishment of mouse Xkr8 ⁇ / ⁇ fetal thymocytes (b). Structures of wild-type, floxed, and deletion-type mXkr8 chromosomal genes and their targeting vectors.
- mice Xkr8 ⁇ / ⁇ fetal thymocytes (c). Treat Xkr8 flox / flox IFET cells, Xkr8 -/- IFET cells, and Xkr8 -/- IFET cells and TMEM16F -/- IFET cells transformed with Xkr8 with FasL, Cy5-Annexin V and PI, or anti-active type Stained with caspase-3. Establishment of mouse Xkr8 ⁇ / ⁇ fetal thymocytes (d).
- Wild type, Xkr8 ⁇ / ⁇ and TMEM16F ⁇ / ⁇ IFET cells were treated with A23187 in the presence of Cy5-Annexin V and Annexin V binding to the cells was monitored by flow cytometry. Effect of Xkr8 knockdown on FasL-induced PtdSer exposure in Ba / F3 cells (a). Real-time PCR for mXkr8 in Ba / F3-Fas clones transformed with retrovirus with mXkr8 shRNA or scrambled shRNA. Effect of Xkr8 knockdown on FasL-induced PtdSer exposure in Ba / F3 cells (b).
- Ba / Fas-Fas and its mXkr8 shRNA-expressing transformants (2 clones each) were treated with FasL and stained with Cy5-Annexin V. Effect of hXkr8 on Ca-dependent PdtSer exposure. PLB-985 and its hXkr8 transformant were treated with 1.0 ⁇ M A23187 and Cy5-labeled Annexin V at 20 ° C., and binding of Annexin V to the cells was monitored by flow cytometry for 10 minutes.
- Xkr8 is a membrane protein having a 6-transmembrane region.
- the nucleotide sequences of human and mouse Xkr8 are disclosed in GenBank NM_018053 and GenBank NM_201368.
- the amino acid sequence of Xkr8 of mouse, rat, human, puffer fish, medaka, and Xenopus is shown in FIG. 5a.
- the “candidate substance for regulating the function of Xkr8” may be a natural substance or a synthetic substance, and is a cell extract of a low molecular weight compound, protein, nucleic acid molecule, peptide, antibody, microorganism, plant, or animal. Product or culture supernatant.
- Candidate substances may be provided in the form of a library, such as a library of small molecule compounds, peptides, or antibodies.
- Xkr8-expressing cells include cells that naturally express Xkr8 from its genome and cells that express Xkr8 from a gene encoding Xkr8 introduced into the cells.
- the cell may be a human, monkey, mouse, or rabbit cell, but is not limited thereto.
- human HeLa, human EBV (Epstein Barr Virus) transformed B cell line, mouse MEF (embryonic fibroblast), and mouse pro B cell line Ba / F3 can be used. it can.
- Methods for introducing Xkr8-encoding genes into cells to produce Xkr8-expressing cells are well known in the art (Molecular® Cloning: A Laboratory Manual (Fourth Edition), Cold Spring Harbor Laboratory Press).
- “Substances that regulate the function of Xkr8” include “substances that enhance the function of Xkr8” and “substances that suppress the function of Xkr8”.
- “enhancing (or suppressing) the function of Xkr8” means enhancing (or inhibiting) the function of Xkr8 as a phospholipid scrambling in a cell or animal.
- the “substance that modulates the function of Xkr8” may be a substance that directly or indirectly affects the function of Xkr8, or a substance that increases or decreases the expression of Xkr8.
- a substance that increases or decreases the expression of Xkr8 includes a substance that increases or decreases the expression of mRNA from a gene encoding Xkr8, and a substance that increases or decreases the protein expression of Xkr8. Therefore, “substances that regulate the function of Xkr8” include substances that act on regulatory sequences such as promoters or enhancers of the gene encoding Xkr8, and antisense oligos prepared based on the sequence of the gene encoding Xkr8. Nucleotides (DNA or RNA), siRNA, miRNA, ribozymes and the like are included. In addition, since Xkr8 is cleaved and activated by caspases, “substances that regulate the function of Xkr8” include substances that increase or decrease the cleavage of Xkr8 by caspases.
- the enzyme activity of Xkr8 as a phospholipid scramblase is measured.
- the phospholipid is selected from phosphatidylserine (PtdSer), phosphatidylethanolamine (PtdEtn), phosphatidylcholine (PtdCho), and sphingomyelin (SM).
- PtdSer and PtdEtn are distributed in the inner leaflet of the cell membrane
- PtdCho and SM are distributed in the outer leaflet of the cell membrane.
- Xkr8 moves PtdSer and PtdEtn to the outer membrane (ie, exposes PtdSer and PtdEtn) and moves PtdCho and SM to the inner membrane (ie, takes up PtdCho and SM).
- the enzyme activity of Xkr8 can be measured by examining the lipid distribution in the cell membrane.
- Candidate substances that increase (increase exposure) the distribution of PtdSer or PtdEtn in the outer cell membrane of the PtdSer or PtdEtn compared to the control are selected as “substances that enhance the function of Xkr8”
- Candidate substances that reduce distribution (decrease exposure) in the outer leaves are selected as “substances that inhibit the function of Xkr8”.
- Candidate substances that increase the distribution (increase uptake) of PtdCho or SM in the inner membrane of PtdCho or SM compared to the control are selected as “substances that enhance the function of Xkr8”, and the cell membrane of PtdCho or SM compared to the control.
- Candidate substances that reduce the distribution in the inner lobe (decrease uptake) are selected as “substances that inhibit the function of Xkr8”.
- control means the distribution of the same lipid in the same cell membrane layer (outer leaf or inner leaf) of Xkr8-expressing cells in the absence of a candidate substance.
- the candidate substance is a culture medium of an Xkr8-expressing cell in the presence of an apoptosis-inducing stimulus.
- Apoptosis-inducing stimuli include apoptosis-inducing molecules such as FasL, staurosporine, and UV irradiation.
- the apoptosis-inducing stimulus can be given to the cells before, simultaneously with, or after the addition of the candidate substance to the medium.
- the distribution of PtdSer in the cell membrane is examined by detecting the binding between PtdSer exposed on the cell surface and a substance capable of binding to PtdSer (for example, AnnexinV or MFG-E8 (also called lactadherin)) be able to.
- a substance capable of binding to PtdSer for example, AnnexinV or MFG-E8 (also called lactadherin)
- AnnexinV or MFG-E8 also called lactadherin
- the distribution of PtdSer in the cell membrane can also be examined based on the blood coagulation reaction. For example, in the presence of an apoptosis-inducing stimulus, Xkr8 expressing cells are mixed with candidate substances and substances required for blood clotting (eg, Factor Xa, Factor Va, or prothrombin) and thrombin production is measured. Alternatively, fibrinogen may be further added to the medium to measure fibrin production.
- candidate substances and substances required for blood clotting eg, Factor Xa, Factor Va, or prothrombin
- fibrinogen may be further added to the medium to measure fibrin production.
- the distribution of PtdEtn in the cell membrane can be examined by detecting the binding between PtdEtn exposed on the cell surface and a substance having a binding property to PtdEtn (for example, RO09-0198 which is a PtdEtn-binding peptide).
- a substance having a binding property to PtdEtn for example, RO09-0198 which is a PtdEtn-binding peptide.
- RO09-0198 which is a PtdEtn-binding peptide
- the distribution of PtdCho and SM in the cell membrane can be measured with fluorescently labeled lipids.
- fluorescent label NBD, TopFluor and the like can be used.
- the fluorescently labeled lipid is added to the culture medium of Xkr8-expressing cells, the fluorescently labeled lipid is incorporated into the outer cell membrane of Xkr8-expressing cells.
- Xkr8 functions as a lipid scrambling, the fluorescently labeled lipid moves (ie, is taken up) to the inner leaf of the cell membrane.
- Xkr8-expressing cells were treated with a candidate substance together with an apoptosis-inducing stimulus, and then the cells were treated with BSA and the fluorescently labeled lipids that were not taken up And the fluorescence-labeled lipid incorporated into the cells may be measured by flow cytometry.
- Xkr8 is involved in PtdSer exposure in apoptotic cells. Therefore, the method of the present invention is useful for the development of therapeutic agents for diseases involving apoptosis.
- Diseases involving apoptosis include brain diseases such as autoimmune diseases, cancer, AIDS, and Alzheimer's disease.
- Mouse interleukin (IL-3) dependent Ba / F3 cells 50 are RPMI (10% fetal calf serum (FCS, Gibco), 45 units / ml mouse) IL-3 and 50 ⁇ M ⁇ -mercaptoethanol).
- Human PLB-985 51 , Jurkat (ATCC TIB152), Namalwa (ATCC CRL-1432), and Raji (ATCC CCL-86) cells were grown in RPMI1640 (containing 10% FCS and 50 ⁇ M ⁇ -mercaptoethanol).
- Plat-E packaging cells 52 were grown in DMEM (containing 10% FCS).
- Recombinant mouse IL-3 53 and human FasL 54 were prepared as previously reported.
- Mouse anti-human ICAD mAb was obtained from Medical & Biological Laboratories (MBL) and Alexa 488- and Alexa 568-labeled goat anti-rabbit IgG were obtained from Invitrogen. Staurosporine was provided by Kyowa Hakko Kirin.
- Retrovirus was produced in Plat-E cells using plasmid DNA from the cDNA library, concentrated by centrifugation, and infected with Ba / F3 cells as previously reported 55 .
- Cells treated with A23187 were stained on ice for 15 minutes with Cy5-Annexin V (Biovision) and 2 minutes with 5 ⁇ g / ml propidium iodide (PI) and sorted with FACSAria (BD Biosciences).
- the cDNA incorporated into the retroviral vector was identified by PCR using a DNA derived from a Ba / F3 cell transformant as previously reported 55 .
- the primers used are as follows (in each primer, the Bam HI or Eco RI recognition sequence is underlined): mXkr8: 5'-ATAT GGATCC ATCATGCCTCTGTCCGTGCACCA-3 '(SEQ ID NO: 7) and 5'-ATAT GAATTC GAGGACTCCATTCAGCTGCA-3' (SEQ ID NO: 8) hXkr8: 5'-ATAT GGATCC GCCATGCCCTGGTCGTCCCGCGG-3 '(SEQ ID NO: 9) and 5'-ATAT GAATTC TCCCTTCACTGGCGAAGCAG-3' (SEQ ID NO: 10) PMXs puro c-GFP was constructed by inserting the GFP sequence between the Eco RI and Xho I sites of pMXs puro.
- Xkr8 cDNA was inserted into the Bam HI / Eco RI site of pMXs puro c-FLAG 55 or pMXs puro c-GFP to express a protein having a FLAG tag or a GFP tag at the C terminus.
- mXkr8 2DA 5'-GGGACCCTGCCCTCGTGGCTGGGACCCTAG-3 ', (SEQ ID NO: 11) and 5'-CTAGGGTCCCAGCCACGAGGGCAGGGTCCC-3' (SEQ ID NO: 12)
- hXkr8 2DA 5'-AAGCCCGACCCTGCCCAGGTAGCCGGGGCC-3 '(SEQ ID NO: 13) and 5'-GGCCCCGGCTACCTGGGCAGGGTCGGGCTT-3' (SEQ ID NO: 14)
- PCR was performed using the following mutant reverse primer: 5'-CGAGATCT GAATTC TCAGTCT
- shRNA Four types of shRNA expression plasmids in pRS shRNA vector having puromycin resistance gene for mXkr8 were purchased from OriGene. Of the four sequences, the optimal target sequence for shRNA was 5′-GAATCTGTGCCATCGCCTTGTTCTCAGCT-3 ′ (SEQ ID NO: 16). Scrambled shRNA in pRS was also purchased from OriGene. Ba / F3 was infected with retrovirus containing shRNA and introduced into WR19L by electroporation. Stable transformants were cloned by limiting dilution by culturing in a medium containing 1.0 ⁇ g / ml puromycin. Xkr8 mRNA was quantified by real-time RT-PCR.
- a diphtheria toxin A fragment (DT-A) induced by the thymidine kinase (tk) promoter was inserted at the 5 ′ end of the vector.
- a targeting vector was introduced into mouse Bruce-4h embryonic stem (ES) cells 58 and G418 resistant clones were screened for homologous recombination by PCR. Positive clones were injected into blastocysts to generate Xkr8 + / NeoFRT mice.
- CAG cytomegalovirus enhancer-avian ⁇ -actin hybrid promoter
- FLPe flippase mutant
- Immortalized fetal thymocyte cell line was established by immortalizing fetal thymocytes with H-ras V12 and c-myc as previously reported 60, 61 .
- IFET immortalized fetal thymocyte cell line
- Xkr8 + / flox mice were mated and fetal thymocytes were obtained at embryonic day (E) 14.5 days.
- Retroviruses with H-ras V12 and c-myc genes are produced in Plat-E cells using pCX4 vector 62 and centrifuged in RetroNectin coated plates (Takara Bio) at 2,000 xg for 2-3 hours at room temperature Were combined.
- Thymocytes were allowed to adhere to retrovirus-coated plates by centrifugation at 400 xg for 5 minutes, and DMEM (10% FCS, 1 x non-essential amino acid, 10 mM Hepes-NaOH buffer (pH 7.4), 50 ⁇ M ⁇ -Cultured in mercaptoethanol, 5 ng / ml mouse IL-7 63 (PeproTech), and GlutaMax TM (Gibco).
- the obtained IFET cells were infected with Adeno-Cre (Adenovirus Cre / loxP, Takara Bio) and cloned by limiting dilution.
- a clone having Xkr8 ⁇ / ⁇ allele was selected by PCR using the following primers (wild-type specific sense primer: 5′-CTCATTGCTGATGTGGGTGACAATA-3 ′ (SEQ ID NO: 17); mutant-specific sense primer: 5 ′ -AGGCTTTTCTCTACTTTTGATGGAG-3 '(SEQ ID NO: 18); and common antisense primer: 5'-CATTATCTTCCTCACTGGCTGAATC-3' (SEQ ID NO: 19)).
- Mouse Fas cDNA 64 was introduced into IFET cells by transformation with retrovirus, and its expression was confirmed by flow cytometry with anti-mouse Fas mAb (Jo2) 65 .
- Human PLB-985 and mouse WR19L cells were transformed by retroviral infection with an amphotropic retrovirus envelope or a VSV ⁇ envelope.
- pMXs retrovirus vector, pGP (Takara Bio) (for gag-pol fusion protein), and pE-ampho (Takara Bio) or pCMV-VSV-G-RSV-Rev provided by Dr. Miyoshi, RIKEN
- Viral particles in the culture supernatant were concentrated by centrifugation to transform the cell line.
- pMXs puroXkr8-GFP was introduced into 293T cells by lipofection using Fugene 6 (Promega). Stable transformants were selected on medium containing 1.0 ⁇ g / ml puromycin.
- cells (1 x 10 6 cells) were fixed by incubating in PBS containing 1% paraformaldehyde (PFA) at 37 ° C for 10 minutes. After washing with chilled PBS containing 0.5% BSA, the cells were permeabilized by incubating overnight in 90% methanol at -20 ° C. Cells were then incubated with 200-fold diluted rabbit anti-active caspase 3 at room temperature for 30 minutes, followed by incubation with 1,000-fold diluted Alexa 488- or Alexa 568 labeled goat anti-rabbit IgG for 30 minutes. After washing with PBS containing 0.5% BSA, the cells were filtered into FACS tubes and analyzed by FACSAria.
- PFA paraformaldehyde
- a portion (150 ⁇ l) was mixed with 150 ⁇ l HBSS (containing 5 ⁇ g / ml fatty acid-free BSA (Sigma-Aldrich) and 500 nM Sytoxblue (Molecular Probes)) and analyzed by FACSAria.
- HBSS containing 5 ⁇ g / ml fatty acid-free BSA (Sigma-Aldrich) and 500 nM Sytoxblue (Molecular Probes)
- DNA was modified with bisulfite using a kit (MethyEasy Xceed, Human Genetic Signatures). To explain, 3 ⁇ g of DNA was denatured by incubating in 0.3 M NaOH for 15 minutes at 37 ° C. and treated with sodium bisulfite according to the supplier's protocol except that the incubation time was changed to 90 minutes. The modified DNA was denatured at 95 ° C. for 20 minutes and amplified by PCR using primers specific to the treated DNA (TTAGGGATTAGAATGTGTTT (SEQ ID NO: 20) and CCTATACAAATAACCCAACT (SEQ ID NO: 21)). PCR was performed with EpiTaq HS polymerase (Takara Bio) for 7-40 cycles and the product was cloned into pGEM-Teasy vector for sequencing.
- Method Method for bisulfite genome sequencing.
- RNA from human and mouse cell lines and various mouse tissues was reverse transcribed using Superscript III reverse transcriptase (Invitrogen) or High Capacity RNA-to-cDNA TM kit (Applied Biosystems). A portion of the product was amplified in a reaction mixture containing LightCycler TM 480 SYBR Green I Master (Roche Diagnostics).
- Primers for real-time RT-PCR are as follows: mXkr8: 5'-GCGACGCCACAGCTCACACT-3 '(SEQ ID NO: 22) and 5'-CCCCAGCAGCAGCAGGTTCC-3' (SEQ ID NO: 23) mGapdh: 5'-AGCAGGCATCTGAGGGCCCA-3 '(SEQ ID NO: 24) and 5'-GAGAGCAATGCCAGCCCCGG-3' (SEQ ID NO: 25) hXkr8: 5'-AGGCCGGGCCATCATCCACT-3 '(SEQ ID NO: 26) and 5'-TGCGCCTGTTCTGAGGCAGC-3' (SEQ ID NO: 27) Human ⁇ -actin: 5′-GCATCCTCACCCTGAAGTAC-3 ′ (SEQ ID NO: 28) and 5′-CTTAATGTCACGCACGATTTC-3 ′ (SEQ ID NO: 29) Specific mRNA was quantified when the LightCycler System detected the onset of
- membrane protein (20 ⁇ g) was added to 3 units of each recombinant human caspase (Biovision), 50 mM Hepes-NaOH (pH 7.4), 50 mM NaCl, 1 hour at 37 ° C. Incubated in 5% (v / v) glycerol, 5 mM DTT, 10 mM EDTA, 0.1 mM APMSF, and 0.1% CHAPS (100 ⁇ l) and analyzed by Western blotting.
- Proteins were separated by electrophoresis on a 10-20% gradient SDS-PAGE (Bio Craft) and transferred to a PVDF membrane (Millipore). 3000-fold diluted mouse anti-GFP mAb, 3000-fold diluted mouse anti-human ICAD mAb, or 3000-fold diluted rabbit anti-active caspase 3 mAb was bound to the membrane, followed by 1,000-fold diluted HRP-conjugated goat anti-mouse or rabbit immunoglobulin (Dako ). Peroxidase activity was detected by Western Lightning TM -ECL system (PerkinElmer).
- mice Xkr8 Cloning of mouse Xkr8
- the present inventors have previously repeated sorting and proliferating cells exposed to a large amount of PtdSer by FACS, so that a subline of mouse Ba / F3 cells expressing PtdSer at a high level ( Ba / F3-PS19) 15 which has been established.
- TMEM16F a Ca 2+ -dependent phospholipid scramblase, was isolated from a Ba / F3-PS19 cDNA library constructed with a cDNA of 2.5 kb or more.
- a cDNA library was prepared from Ba / F3-PS19 cDNA having a length of 1.0 to 2.5 kb and introduced into Ba / F3 cells. Sorting and growth of cells that efficiently exposed PtdSer by FACS were repeated 5 times, and the selected cells were subjected to limiting dilution. By this step, a cell line (LD-PS5-2-2) that constantly exposes PtdSer was established (FIG. 1a). In LD-PS5-2-2 cells, only cDNA encoding mouse Xkr8, a 401 amino acid protein having a plurality of transmembrane regions, was incorporated.
- FasL Fas ligand
- DNA was prepared from PLB-985, Raji, and Namalwa cells, and peripheral blood leukocytes from healthy individuals, and bisulfite (bisulfite) ) Analyzed by DNA sequencing 19 .
- DNA derived from peripheral blood leukocytes, Jurkat cells, or Namalwa cells none of the 23 CpG sites was methylated (FIG. 3b).
- PLB-985 cells and Raji cells all CpG sites were severely methylated or with a probability of 90% or more.
- Scramblease activity via Xkr8 Phospholipid scramblase is defined as an enzyme that can move phospholipids non-specifically in the cell membrane 20 .
- human PLB-985 and its transformants expressing hXkr8 were treated with staurosporine. After 4 hours, ICAD (ICAD-L and ICAD-S) was similarly well cleaved in PLB-985 and its hXkr8 expressing transformants (FIG. 4a).
- NBD-PC and NBD-SM were incorporated in hXkr8 transformants treated with staurosporine, but not in parental cells. These results indicate that Xkr8 is activated during apoptotic cell death and functions as a non-specific scramblase. This non-specific scrambling activity of Xkr8 was similar to TMEM16F, a Ca 2+ -dependent phospholipid scrambling 15 . However, unlike apoptosis-induced PtdSer exposure, Ca 2+ -induced PtdSer exposure occurs in PLB-985 cells and hXkr8 transformants at the same rate (FIG. 8), indicating that Xkr8 is Ca 2+ dependent. This suggests that PtdSer exposure is not affected.
- Xkr8 Activation of Xkr8 by caspases Xkr8 is a member of the XK family 22 and its homologs are present in mammals, fish and amphibians (FIG. 5a).
- topology prediction programs including TMpred (http://www.ch.embnet.org/software/TMPRED_form.html) and TMHMM (http://www.cbs.dtu.dk/services/TMHMM-2.0/) Analysis of the amino acid sequence of Xkr8 from various sources resulted in a prediction mismatch of 6 to 8 transmembrane regions.
- Xkr8 is thought to have six transmembrane regions and the N-terminus and C-terminus are present in the cytoplasm (FIG. 5b).
- CASVM online search tool
- Apoptotic PtdSer exposure is often caspase-dependent 24 .
- the presence of a caspase recognition sequence in Xkr8 suggests that Xkr8 may be a direct target for caspase-3.
- the P D QV D G sequence of amino acid at position 355 of hXkr8 was mutated to P A QV A G (2DA) (Fig. 5c) Fused to GFP at its C-terminus and introduced into PLB-985 cells.
- hXkr8 is cleaved with Asp-355 (FIG. 5c), fused with GFP or not fused with GFP and introduced into PLB-985 cells, and this cleaved hXkr8 becomes a constitutive active form.
- Asp-355 FIG. 5c
- truncated hXkr8 did not mediate PtdSer exposure in proliferating or apoptotic cells (FIG. 5d). Fluorescence microscopy of human 293T cells expressing the truncated hXkr8-GFP fusion protein indicated that this protein is present in the cytoplasm (possibly in the endoplasmic reticulum) (FIG. 5h).
- Dibasic amino acid motifs R / K (X) R / K
- diaromatic amino acid motifs FF, FY, or YY
- FF, FY, or YY diaromatic amino acid motifs
- Xkr8 -/- fetal thymus cell line PtdSer is exposed to the surface of most apoptotic cells. Therefore, mXkr8 mRNA is expressed at high levels in the testis and is universally and nearly equally expressed in various mouse tissues except that it is low in heart and muscle (FIG. 6a).
- IFET Xkr8-deficient fetal thymocyte cell line
- Sequence number 7 Synthetic primer sequence number 8: Synthetic primer sequence number 9: Synthetic primer sequence number 10: Synthetic primer sequence number 11: Synthetic primer sequence number 12: Synthetic primer sequence number 13: Synthetic primer sequence number 14: Synthetic primer sequence number 15: Synthetic primer sequence number 16: Target sequence number 17 of shRNA: Synthetic primer sequence number 18: Synthetic primer sequence number 19: Synthetic primer sequence number 20: Synthetic primer sequence number 21: Synthetic primer sequence number 22: Synthetic primer sequence number 23: Synthetic primer sequence number 24: Synthetic primer sequence number 25: Synthetic primer sequence number 26: Synthetic primer sequence number 27: Synthetic primer sequence number 28: Synthetic primer sequence number 29: Synthetic primer
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Xkr8の機能を調節する物質のスクリーニング方法であって、以下の工程を含む方法:
(1)Xkr8発現細胞と、Xkr8の機能を調節する物質の候補物質とを接触させる工程、および
(2)該細胞の細胞膜におけるリン脂質の分布を変化させる候補物質を選択する工程。
(1)細胞株、組換タンパク質、抗体、および材料
マウスインターロイキン(IL-3)依存性Ba/F3細胞50は、RPMI(10%ウシ胎児血清(FCS, Gibco)、45 単位/ml マウスIL-3、および50μM β-メルカプトエタノール含有)で維持した。ヒトPLB-98551、Jurkat (ATCC TIB152)、Namalwa (ATCC CRL-1432)、およびRaji (ATCC CCL-86) 細胞は、RPMI1640 (10% FCSおよび50μMβ-メルカプトエタノール含有)にて増殖させた。Plat-Eパッケージング細胞52は、DMEM (10% FCS含有)にて増殖させた。組換マウスIL-353およびヒトFasL54は、既報のとおり調製した。ウサギ抗活性型カスパーゼ3 mAbは、Cell Signalingから入手した。マウス抗ヒトICAD mAbはMedical & Biological Laboratories (MBL)から入手し、Alexa 488- およびAlexa 568- 標識ヤギ抗ウサギIgGはInvitrogenから入手した。スタウロスポリンは協和発酵キリンより提供を受けた。
Ba/F3-PS19細胞由来のポリ(A) RNAを用いて、ランダムヘキサマーをプライマーとして使用して二本鎖cDNAを合成し、BstXIアダプターを既報のとおり連結した55。長さ1.0-2.5 kbのDNA断片を1%アガロースゲルでの電気泳動によりサイズ分画し、Bst XIで消化したpMXsベクター56にライゲートした。E. coli DH10B細胞 (ElectroMax DH10B; Invitrogen) をエレクトロポレーションにより形質転換して、約1.3 x 106 クローンを得た。cDNAライブラリー由来のプラスミドDNAを用いて、Plat-E細胞においてレトロウイルスを産生し、遠心分離により濃縮し、既報のとおりBa/F3細胞に感染させた55。A23187で処理した細胞を、氷上で、Cy5-Annexin V (Biovision)により15分間、および5μg/ml ヨウ化プロピジウム (PI)により2分間、染色し、FACSAria (BD Biosciences)でソートした。レトロウイルスベクターに組み込まれたcDNAは、Ba/F3細胞形質転換体由来のDNAを用いて、既報のとおりPCRにより同定した55。
mXkr8 (GenBank NM_201368) およびhXkr8 (GenBank NM_018053) の全長コーディング配列を、それぞれBa/F3細胞およびNamalwa細胞からRT-PCRにより調製した。使用したプライマーは以下のとおりである(各プライマーにおいて、Bam HIまたはEco RI 認識配列を下線で示す。):
mXkr8: 5’-ATATGGATCCATCATGCCTCTGTCCGTGCACCA-3’ (配列番号7)および 5’-ATATGAATTCGAGGACTCCATTCAGCTGCA-3’ (配列番号8)
hXkr8: 5’-ATATGGATCCGCCATGCCCTGGTCGTCCCGCGG-3’ (配列番号9)および5’-ATATGAATTCTCCCTTCACTGGCGAAGCAG-3’ (配列番号10)
GFP配列をpMXs puroのEco RI部位とXho I部位の間に挿入することにより、pMXs puro c-GFPを構築した。次いで、Xkr8 cDNAをpMXs puro c-FLAG55またはpMXs puro c-GFPのBam HI/Eco RI部位に挿入し、C末端にFLAGタグまたはGFPタグを有するタンパク質を発現させた。mXkr8のD351A/D354A (2DA)変異体およびhXkr8のD352A/D355A (2DA) 変異体を作成するため、マウスおよびヒトXkr8 cDNAを、変異ヌクレオチドを有する以下の30ヌクレオチドのプライマーを用いた組換PCR57により変異させた:
mXkr8 2DA: 5’-GGGACCCTGCCCTCGTGGCTGGGACCCTAG-3’, (配列番号11)および 5’-CTAGGGTCCCAGCCACGAGGGCAGGGTCCC-3’ (配列番号12)
hXkr8 2DA: 5’-AAGCCCGACCCTGCCCAGGTAGCCGGGGCC-3’ (配列番号13)および5’-GGCCCCGGCTACCTGGGCAGGGTCGGGCTT-3’ (配列番号14)
hXkr8のC末端欠失変異体を構築するため、以下の変異型リバースプライマー: 5’-CGAGATCTGAATTCTCAGTCTACCTGGTCAGGGTCGG-3’ (配列番号15)(Eco RI認識配列を下線で示す)を用いてPCRを行い、pMXs puroベクターに挿入した。
mXkr8のための、ピューロマイシン抵抗性遺伝子を有するpRS shRNAベクターにおけるshRNA発現プラスミド4種類は、OriGeneより購入した。4つの配列のうち、shRNAに最適な標的配列は5’-GAATCTGTGCCATCGCCTTGTTCTCAGCT-3’ (配列番号16)であった。pRSにおけるスクランブルshRNAもまた、OriGeneより購入した。Ba/F3にshRNAを含むレトロウイルスを感染させ、WR19Lにはエレクトロポレーションにより導入した。1.0μg/mlピューロマイシンを含む培地中で培養することにより安定な形質転換体を限界希釈によりクローニングした。Xkr8 mRNAはリアルタイムRT-PCRにより定量した。
Xkr8をコンディショナルに標的化したマウスは、Unitechに特別注文して作成した。 説明すると、FRT配列で挟まれたホスホグリセリン酸キナーゼ(PGK) プロモーター誘導性ネオマイシン耐性(neo) 遺伝子を有するneo-loxP カセットをXkr8遺伝子のイントロン3に挿入した。エクソン3を含む1.0-kbのDNAフラグメントを対応する配列とP1 (loxP)配列において交差する遺伝子座を有するフラグメントと置き換えた。チミジンキナーゼ (tk) プロモーターに誘導されるジフテリア毒素A断片 (DT-A)をベクターの5’末端に挿入した。マウスBruce-4h胚性幹 (ES) 細胞58にターゲティングベクターを導入し、G418耐性クローンをPCRにより相同組換についてスクリーニングした。陽性クローンを胚盤胞に注射し、Xkr8+/NeoFRTマウスを作成した。Xkr8+/NeoFRT マウスを、サイトメガロウイルスエンハンサー-トリβ-アクチンハイブリットプロモーター(CAG)誘導性のフリッパーゼ変異体 (FLPe) 遺伝子(CAG-FLPe)59を有するトランスジェニックマウスと交配し、得られたマウスをC57BL/6に戻し交配して、Xkr8+/floxマウスを得た。いずれのマウスも京都大学における特定の飼育室(SPF, 特定された微生物や寄生虫が存在しない飼育室)で飼育し、動物実験は全て京都大学に認可されたプロトコールにしたがって実施した。
不死化胎児胸腺細胞株 (IFET) は、胎児胸腺細胞を既報のとおりH-rasV12およびc-mycにより不死化することで樹立した60, 61。説明すると、Xkr8+/floxマウス同士を交配し、胎児胸腺細胞を胎生 (E) 14.5日で得た。H-rasV12 およびc-mycの遺伝子を有するレトロウイルスを pCX4ベクター62を用いてPlat-E細胞で産生し、RetroNectinコートプレート (Takara Bio) に、室温で2,000 x gにて2-3時間遠心分離することにより結合させた。400 x gにて5分間遠心分離することにより、レトロウイルスをコートしたプレートに胸腺細胞を接着させ、DMEM(10% FCS、1 x 非必須アミノ酸、10 mM Hepes-NaOHバッファー (pH 7.4)、50μM β-メルカプトエタノール、5 ng/ml マウスIL-763 (PeproTech)、およびGlutaMax(商標) (Gibco)含有)にて培養した。得られたIFET細胞にAdeno-Cre (Adenovirus Cre/loxP, Takara Bio)を感染させ、限界希釈によりクローニングした。Xkr8-/-アリルを有するクローンを、以下のプライマーを用いたPCRにより選択した (野生型特異的センスプライマー: 5’-CTCATTGCTGATGTGGGTGACAATA-3’ (配列番号17); 変異型特異的センスプライマー: 5’-AGGCTTTTCTCTACTTTTGATGGAG-3’ (配列番号18); および共通のアンチセンスプライマー: 5’-CATTATCTTCCTCACTGGCTGAATC-3’ (配列番号19))。
pMX-puroベクターをPlat-E細胞に導入することにより、マウスおよびヒトXkr8cDNAを有するレトロウイルスを作製し、遠心分離により濃縮し、Ba/F3細胞およびXkr8-/- IFET細胞に感染させた。安定な形質転換体を、ピューロマイシン含有培地(Ba/F3細胞について1.0μg/ml、IFET細胞について2.0μg/ml)にて選択し、組換タンパク質の発現を抗Flag (Clone M2, Sigma)または抗GFP (Clone JL8, Clontech)によるウェスタンブロッティングにより確認した。レトロウイルスによる形質転換によってマウスFas cDNA64をIFET細胞に導入し、その発現を抗マウスFas mAb (Jo2)65によるフローサイトメトリーにより確認した。ヒトPLB-985およびマウスWR19L細胞を両種性レトロウイルスエンベロープまたはVSVγエンベロープによるレトロウイルス感染により形質転換した。説明すると、pMXsレトロウイルスベクター、pGP (Takara Bio) (gag-pol融合タンパク質用)、およびpE-ampho (Takara Bio)またはpCMV-VSV-G-RSV-Rev (理化学研究所三好博士より供与)を一緒に293T細胞に導入することにより、レトロウイルスを産生した。培養上清中のウイルス粒子を遠心分離により濃縮し、細胞株を形質転換した。Xkr8-GFPを293T細胞で発現させるため、Fugene 6 (Promega)を用いたリポフェクションにより、293T細胞にpMXs puroXkr8-GFPを導入した。安定な形質転換体は、1.0μg/ml ピューロマイシンを含む培地で選択した。
細胞にFasLまたはスタウロスポリンを処理し、あるいはUV照射し、アポトーシスを誘導した。説明すると、5 x 105細胞(培養培地500μl中)を、37℃で、10-400単位/ml hFasLと1.2-2.0時間、あるいは10μM スタウロスポリンと1.5-4.0時間、インキュベートした。UV照射では、StrataLinker UVオーブン (Stratagene)において、1 x 106細胞(PBS2 ml中)に500-2000 J/m2 (254 nm)にてUV照射し、10% FCS含有RPMI1640(4 ml)中で37℃にて1.5-2.0時間インキュベートした。Ca2+イオノフォア誘発PtdSer露出をモニターするため、細胞 (5 x 105細胞)をAnnexin V染色バッファー (10 mM Hepes-NaOHバッファー [pH7.4]、140 mM NaClおよび2.5 mM CaCl2含有) 500μl中で20℃にて3分間インキュベートし、3.0-10μM A23187で処理し、FACSAriaで20℃にて解析した。
細胞表面に露出するPtdSerおよびPtdEtnを検出するため、細胞を氷上で2500-5000倍希釈のCy5-Annexin V (Biovision)または800倍希釈のビオチン-Ro09-019866で15分間染色し、続いて1.0μg/ml APC-ストレプトアビジン (Annexin V染色バッファー中)により5μg/mlヨウ化プロピジウム(PI)の存在下染色し、FACSAriaまたはFACSCalibur (BD Biosciences)により解析した。PtdChoおよびSMの取り込みを評価するため、1 x 106細胞 (1 mM CaCl2含有HBSS (HBSS-Ca) 0.5 ml 中)を氷上で7分間インキュベートした。等量の200 nM 1-オレイル-2-{6-[(7-ニトロ-2-1,3-ベンゾオキサジアゾール-4-イル)アミノ]ヘキサノイル}-sn-グリセロ-3-ホスホコリン(NBD-PC)(Avanti Polar Lipids)またはN-[6-[(7-ニトロ-2-1,3-ベンゾオキサジアゾール-4-イル)アミノ]ヘキサノイル]-スフィンゴシン-1-ホスホコリン(NBD-SM) (Avanti Polar Lipids) (HBSS-Ca中)を添加し、20℃でインキュベートした。一部(150μl)を150μl HBSS (5μg/ml 脂肪酸不含BSA (Sigma-Aldrich)および500 nM Sytoxblue (Molecular Probes)含有)と混合し、FACSAriaにより解析した。
ヒトPLB-985細胞を5-アザ-2’-デオキシシチジン (DAC, Sigma-Aldrich)で処理するため、1.0 x 106細胞(10% FCS含有RPMI10 ml中)を0.5 mM DACと7日間インキュベートした。DACは不安定な化合物であるため、DAC含有培地は24時間毎に交換した。DAC処理後、細胞を3つに分けた。1つはPtdSer露出の解析のためのFACS用、1つはXkr8遺伝子発現のためのリアルタイムRT-PCR 用、1つはメチル化特異的PCR解析用である67。バイサルファイトゲノムシークエンスのため、キット(MethyEasy Xceed, Human Genetic Signatures)を用いてDNAを亜硫酸水素塩で修飾した。説明すると、3μgのDNAを37℃で15分間0.3 M NaOH中でインキュベートすることにより変性させ、インキュベーション時間を90分に変更した点を除き供給元のプロトコールにしたがい亜硫酸水素ナトリウムで処理した。修飾したDNAを95℃で20分間変性させ、処理したDNAに特異的なプライマー(TTAGGGATTAGAATGTGTTT (配列番号20)および CCTATACAAATAACCCAACT (配列番号21))を用いてPCRにより増幅した。EpiTaq HSポリメラーゼ (Takara Bio) を用いてPCRを7-40サイクル実施し、配列決定のため生成物をpGEM-Teasyベクターにクローニングした。
ヒトおよびマウス細胞株並びに様々なマウス組織に由来する全RNAを、Superscript III 逆転写酵素 (Invitrogen) またはHigh Capacity RNA-to-cDNA(商標) キット (Applied Biosystems)を用いて逆転写した。生成物の一部を、LightCycler(商標)480 SYBR Green I Master (Roche Diagnostics)を含む反応混合物中で増幅した。リアルタイムRT-PCR用のプライマーは以下のとおりである:
mXkr8: 5’-GCGACGCCACAGCTCACACT-3’ (配列番号22)および 5’-CCCCAGCAGCAGCAGGTTCC-3’ (配列番号23)
mGapdh: 5’-AGCAGGCATCTGAGGGCCCA-3’ (配列番号24)および 5’-GAGAGCAATGCCAGCCCCGG-3’ (配列番号25)
hXkr8: 5’-AGGCCGGGCCATCATCCACT-3’ (配列番号26)および 5’-TGCGCCTGTTCTGAGGCAGC-3’ (配列番号27)
ヒトβ-アクチン: 5’-GCATCCTCACCCTGAAGTAC-3’ (配列番号28)および5’-CTTAATGTCACGCACGATTTC-3’ (配列番号29)
特異的mRNAは、LightCycler Systemが参照としてのそれぞれの直線化プラスミドDNAについてPCRによる集積の対数期の立ち上がりを検出した時点で、定量した。
hXkr8-GFPまたはhXkr8 2DA-GFPを発現するPLB-985細胞形質転換体から、既報のとおり膜画分を調製した53。次いで、膜を溶解バッファー (20 mM Tris-HCl [pH 7.2]、140 mM NaCl、1% Triton X-100、10% グリセロール、および1 mM (p-アミノフェニル) メタンスルホニルフルオリド (APMSF))に懸濁することにより可溶化した。不溶性物質を遠心分離により除去した後、膜タンパク質 (20μg) を、37℃で1時間、3単位の各組換ヒトカスパーゼ (Biovision)と、50 mM Hepes-NaOH (pH 7.4)、50 mM NaCl、5% (v/v) グリセロール、5 mM DTT、10 mM EDTA、0.1 mM APMSF、および0.1% CHAPS(100μl)中でインキュベートし、ウェスタンブロッティングにより解析した。
RIPAバッファー (50 mM Hepes-NaOH バッファー [pH 8.0]、1% NP-40、0.1% SDS、0.5%デオキシコール酸ナトリウム、150 mM NaCl、および10%プロテアーゼ阻害剤カクテル)中で細胞を溶解した。溶解物を5 x SDSサンプルバッファー (200 mM Tris-HCl [pH 6.8]、10% SDS、25% グリセロール、5% β-メルカプトエタノール、および0.05% ブロモフェノールブルー)と混合し、Xkr8-GFPの検出のため室温で1時間インキュベートし、あるいは他のタンパク質の検出のため5分間煮沸した。タンパク質を10-20%勾配SDS-PAGE (Bio Craft)上の電気泳動により分離し、PVDF メンブレン (Millipore)に転写した。メンブレンに3000倍希釈マウス抗GFP mAb、3000倍希釈マウス抗ヒトICAD mAb、または3000倍希釈ウサギ抗活性型カスパーゼ3 mAbを結合させ、続いて1,000倍希釈HRP結合ヤギ抗マウスまたはウサギ免疫グロブリン (Dako)とともにインキュベートした。ペルオキシダーゼ活性は、Western Lightning(商標)-ECL システム (PerkinElmer)により検出した。
(1)マウスXkr8のクローニング
本発明者らは以前に、PtdSerを多く露出する細胞をFACSによりソーティングし増殖させることを繰り返すことで、PtdSerを高レベルに発現するマウスBa/F3細胞のサブライン(Ba/F3-PS19)を樹立している15。Ca2+依存性リン脂質スクランブラーゼであるTMEM16Fは、2.5 kb以上のcDNAで構築したBa/F3-PS19のcDNAライブラリーから単離した。アポトーシス性のPtdSer露出に関与するスクランブラーゼを探索するため、長さ1.0~2.5 kbのBa/F3-PS19 cDNAによりcDNAライブラリーを調製し、Ba/F3細胞に導入した。PtdSerを効率的に露出する細胞のFACSによる選別と増殖を5回繰り返し、選別した細胞を限界希釈した。この工程により、恒常的にPtdSer を露出する細胞株(LD-PS5-2-2)を樹立した(図1a)。LD-PS5-2-2細胞には、複数の膜貫通領域を有する401アミノ酸のタンパク質であるマウスXkr8をコードするcDNAのみが組み込まれていた。
以前の報告と一致して17,18、ヒトPLB-985白血病株およびRajiリンパ腫株は、スタウロスポリン、UV、またはFasLなどのアポトーシス性刺激によってPtdSerを発現せず、スタウロスポリンに応答してPtdSerを発現するヒトNamalwa細胞およびJurkat細胞とは非常に対照的であった(図2a)。リアルタイムRT-PCR解析によれば、PLB-985細胞およびRaji細胞におけるXkr8 mRNAレベルは、それぞれNamalwa細胞の8%および9%であった(図2b)。PLB-985細胞またはRaji細胞にhXkr8発現プラスミドを導入すると、これらの形質転換体は、効率的にスタウロスポリン、UV照射、またはFasLに応答してPtdSerを露出し、カスパーゼ活性化は増強しなかった(図2c)。これらの結果は、PLB-985細胞およびRaji細胞がPtdSerを露出できないのはXkr8遺伝子の発現の欠如によることを示唆する。
リン脂質スクランブラーゼは、細胞膜において非特異的にリン脂質を移動させることができる酵素として定義される20。Xkr8を介するスクランブラーゼ活性について調べるため、ヒトPLB-985およびhXkr8を発現するその形質転換体をスタウロスポリンで処理した。4時間後、ICAD (ICAD-LおよびICAD-S)はPLB-985およびそのhXkr8発現形質転換体において同様に十分に切断されていた(図4a)。PtdSer露出で観察されたように、親PLB-985細胞およびhXkr8形質転換体をPtdEtn結合ペプチドであるRO09-019821 (ROペプチド)を用いて解析すると、どちらの細胞も増殖中はPtdEtnを露出しなかった(図4b)。一方、スタウロスポリン処理hXkr8発現PLB-985細胞は、ROペプチドにより染色されPtdEtnの発現が示されたが、親細胞では染色されなかった。PtdChoおよびSMについてのスクランブル活性は、1-オレオイル-2-{6-[(7-ニトロ-2-1,3-ベンゾオキサジアゾール-4-イル)アミノ]ヘキサノイル}-sn-グリセロ-3-ホスホコリン (NBD-PC)、またはN-[6-[(7-nitro-2-1,3- ベンゾオキサジアゾール-4-イル)アミノ] ヘキサノイル]-スフィンゴシン-1-ホスホコリン (NBD-SM)の取り込みにより調べた。図4cおよび4dに示されるように、NBD-PCおよびNBD-SMは増殖中のPLB-985細胞またはhXkr8形質転換体では取り込まれなかった。一方、NBD-PCおよびNBD-SMは、スタウロスポリンを処理したhXkr8形質転換体では取り込まれたが、親細胞では取り込まれなかった。これらの結果は、Xkr8がアポトーシス細胞死の間に活性化され、非特異的スクランブラーゼとして機能することを示す。このXkr8の非特異的スクランブリング活性は、Ca2+依存性リン脂質スクランブラーゼであるTMEM16Fと類似していた15。しかしながら、アポトーシス誘導性のPtdSer露出とは異なり、PLB-985細胞およびhXkr8形質転換体におけるCa2+誘導性のPtdSer露出は同じ速度で生じ(図8)、このことはXkr8がCa2+依存性のPtdSer露出には影響しないことを示唆する。
Xkr8はXKファミリーのメンバーであり22、そのホモログは哺乳類、魚類、および両生類に存在する(図5a)。TMpred (http://www.ch.embnet.org/software/TMPRED_form.html)およびTMHMM (http://www.cbs.dtu.dk/services/TMHMM-2.0/)を含むトポロジー予測プログラムを用いて、各種由来のXkr8のアミノ酸配列の解析により、6つから8つの膜貫通領域という予測の不一致が生じた。Xkr8タンパク質の全体構造が種間で保存されているとすれば、Xkr8は6つの膜貫通領域を有し、N末端およびC末端が細胞質内に存在すると考えられる(図5b)。オンラインサーチツール(CASVM, http://www.casbase.org/casvm/index.html)により、ヒト、マウス、ラット、フグ、メダカ、およびXenopusのXkr8のC末端細胞内領域に、よく保存された カスパーゼ3認識配列23が同定された(図5a)。
PtdSerはアポトーシスを起こしたほとんどの細胞で細胞表面に暴露される。それゆえ、mXkr8 mRNAは、精巣で非常に高く発現し、心臓および筋肉での発現が低い点を除き、様々なマウス組織で普遍的かつほぼ同程度に発現している(図6a)。リン脂質スクランブリングにおけるXkr8の役割を調べ、またそのリン脂質スクランブリング活性をTMEM16Fと比較するため、Xkr8欠損胎児胸腺細胞株 (IFET) を樹立した(図6b)。FasLに応答して、Xkr8flox/flox IFET細胞およびTMEM16F-/- IFET細胞は迅速にPtdSerを露出した(図6c)。これに対して、Xkr8-/- IFET細胞はこの処理に対してPtdSerを露出しなかったが、カスパーゼ3 は同様に活性化されていた。Xkr8-/- IFET細胞にmXkr8 cDNAを有するレトロウイルスを感染させると、この形質転換体はFasLに応答してPtdSerを露出した。一方、Ca2+ イオノフォアはXkr8flox/flo IFET細胞およびXkr8-/- IFET細胞においてPtdSerの露出を誘導したが、TMEM16F-/- IFET細胞では誘導しなかった(図6d)。これらの結果から、Xkr8はアポトーシス性のPtdSer露出に関与し、TMEM16FはCa2+誘導性のPtdSer露出に関与することがわかる。
1. Jacobson, M. D., Weil, M., & Raff, M. C., Programmed cell death in animal development. Cell 88, 347-354 (1997).
2. Vaux, D. L. & Korsmeyer, S. J., Cell death in development. Cell 96, 245-254 (1999).
3. Nagata, S., Apoptosis by death factor. Cell 88, 355-365 (1997).
4. Strasser, A., O'Connor, L., & Dixit, V. M., Apoptosis signaling. Annu. Rev. Biochem. 69, 217-245 (2000).
5. Nagata, S., DNA degradation in development and programmed cell death. Annu. Rev. Immunol. 23, 853-875 (2005).
6. Enari, M. et al., A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391, 43-50 (1998).
7. Coleman, M. et al., Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat. Cell Biol. 3, 339-345 (2001).
8. Sebbagh, M. et al., Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat. Cell Biol. 3, 346-352 (2001).
9. Fadok, V. A. et al., Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148, 2207-2216 (1992).
10. Leventis, P. A. & Grinstein, S., The Distribution and Function of Phosphatidylserine in Cellular Membranes. Annu. Rev. Biophys. 39, 407-427 (2010).
11. Ravichandran, K. S. & Lorenz, U., Engulfment of apoptotic cells: signals for a good meal. Nat. Rev. Immunol. 7, 964-974 (2007).
12. Nagata, S., Hanayama, R., & Kawane, K., Autoimmunity and the clearance of dead cells. Cell 140, 619-630 (2010).
13. Zwaal, R., Comfurius, P., & Bevers, E., Lipid-protein interactions in blood coagulation. Biochim. Biophys. Acta 1376, 433-453 (1998).
14. Bevers, E. & Williamson, P., Phospholipid scramblase: an update. FEBS Lett. 584, 2724-2730 (2010).
15. Suzuki, J., Umeda, M., Sims, P. J., & Nagata, S., Calcium-dependent phospholipid scrambling by TMEM16F. Nature 468, 834-838 (2010).
16. Williamson, P. et al., Phospholipid scramblase activation pathways in lymphocytes. Biochemistry 40, 8065-8072 (2001).
17. Fadeel, B. et al., Phosphatidylserine exposure during apoptosis is a cell-type-specific event and does not correlate with plasma membrane phospholipid scramblase expression. Biochem. Biophys. Res. Commun. 266, 504-511 (1999).
18. Fadok, V. A., de Cathelineau, A., Daleke, D. L., Henson, P. M., & Bratton, D. L., Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J. Biol. Chem. 276, 1071-1077 (2001).
19. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., & Baylin, S. B., Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821-9826 (1996).
20. Balasubramanian, K. & Schroit, A., Aminophospholipid asymmetry: A matter of life and death. Annu. Rev. Physiol. 65, 701-734 (2003).
21. Emoto, K., Toyama-Sorimachi, N., Karasuyama, H., Inoue, K., & Umeda, M., Exposure of phosphatidylethanolamine on the surface of apoptotic cells. Exp. Cell Res. 232, 430-434 (1997).
22. Calenda, G. et al., Identification of two new members, XPLAC and XTES, of the XK family. Gene 370, 6-16 (2006).
23. Timmer, J. C. & Salvesen, G. S., Caspase substrates. Cell Death Differ. 14, 66-72 (2007).
24. Martin, S. J., Finucane, D. M., Amarante-Mendes, G. P., O'Brien, G. A., & Green, D. R., Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity. J. Biol. Chem. 271, 28753-28756 (1996).
25. Giraudo, C. G. & Maccioni, H. J. F., Endoplasmic reticulum export of glycosyltransferases depends on interaction of a cytoplasmic dibasic motif with Sar1. Mol. Biol. Cell. 14, 3753-3766 (2003).
26. Barlowe, C., Signals for COPII-dependent export from the ER: what's the ticket out? Trends Cell Biol. 13, 295-300 (2003).
27. Ho, M. et al., Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell 77, 869-880 (1994).
28. Russo, D., Redman, C., & Lee, S., Association of XK and Kell blood group proteins. The Journal of biological chemistry 273, 13950-13956 (1998).
29. Schoenwaelder, S. M. et al., Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 114, 663-666 (2009).
30. Ricci, J.-E. et al., Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell 117, 773-786 (2004).
31. Gleiss, B., Gogvadze, V., Orrenius, S., & Fadeel, B., Fas-triggered phosphatidylserine exposure is modulated by intracellular ATP. FEBS Lett. 519, 153-158 (2002).
32. Fadeel, B. & Orrenius, S., Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J. Inter. Med. 258, 479-517 (2005).
33. Sandilos, J. K. et al., Pannexin 1, an ATP Release Channel, Is Activated by Caspase Cleavage of Its Pore-associated C-terminal Autoinhibitory Region. J. Biol. Chem. 287, 11303-11311 (2012).
34. Chekeni, F. B. et al., Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 467, 863-867 (2010).
35. Bratton, D. et al., Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J. Biol. Chem. 272, 26159-26165 (1997).
36. Hampton, M., Vanags, D., Porn-Ares, M., & Orrenius, S., Involvement of extracellular calcium in phosphatidylserine exposure during apoptosis. FEBS Lett. 399, 277-282 (1996).
37. van den Eijnde, S. et al., Cell surface exposure of phosphatidylserine during apoptosis is phylogenetically conserved. Apoptosis 3, 9-16 (1998).
38. Venegas, V. & Zhou, Z., Two alternative mechanisms that regulate the presentation of apoptotic cell engulfment signal in Caenorhabditis elegans. Mol. Biol. Cell 18, 3180-3192 (2007).
39. Ellis, R. E., Jacobson, D. M., & Horvitz, H. R., Genes required for the engulfment of cell corpses during programmed cell death in Caenorhabditis elegans. Genetics 129, 79-94. (1991).
40. Stanfield, G. & Horvitz, H., The ced-8 gene controls the timing of programmed cell deaths in C. elegans. Mol. Cell 5, 423-433 (2000).
41. Munoz, L. E., Lauber, K., Schiller, M., Manfredi, A. A., & Herrmann, M., The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. Rheumatol. 6, 280-289 (2010).
42. Franks, A. L. & Slansky, J. E., Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res. 32, 1119-1136 (2012).
43. Yoshida, H. et al., Phosphatidylserine-dependent engulfment by macrophages of nuclei from erythroid precursor cells. Nature 437, 754-758 (2005).
44. Connor, J., Pak, C. C., & Schroit, A. J., Exposure of phosphatidylserine in the outer leaflet of human red blood cells. Relationship to cell density, cell age, and clearance by mononuclear cells. J. Biol. Chem. 269, 2399-2404 (1994).
45. Stowell, S. R. et al., Galectin-1 induces reversible phosphatidylserine exposure at the plasma membrane. Mol. Biol. Cell 20, 1408-1418 (2009).
46. van den Eijnde, S. et al., Transient expression of phosphatidylserine at cell-cell contact areas is required for myotube formation. J. Cell Sci. 114, 3631-3642 (2001).
47. Gadella, B. & Harrison, R., Capacitation induces cyclic adenosine 3',5'-monophosphate-dependent, but apoptosis-unrelated, exposure of aminophospholipids at the apical head plasma membrane of boar sperm cells. Biol. Reprod. 67, 340-350 (2002).
48. Marguet, D., Luciani, M. F., Moynault, A., Williamson, P., & Chimini, G., Engulfment of apoptotic cells involves the redistribution of membrane phosphatidylserine on phagocyte and prey. Nat. Cell Biol. 1, 454-456 (1999).
49. Imao, T. & Nagata, S., Apaf-1- and Caspase-8-independent apoptosis. Cell Death Differ, in press (2012).
50. Palacios, R. & Steinmetz, M., Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 41, 727-734 (1985).
51. Tucker, K. A., Lilly, M. B., Heck, L., & Rado, T. A., Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity. Blood 70, 372-378 (1987).
52. Morita, S., Kojima, T., & Kitamura, T., Plat-E: an efficient and stable system for transient packaging of retroviruses. Gene Ther. 7, 1063-1066 (2000).
53. Fukunaga, R., Ishizaka-Ikeda, E., & Nagata, S., Purification and characterization of the receptor for murine granulocyte colony-stimulating factor. J. Biol. Chem. 265, 14008-14015 (1990).
54. Shiraishi, T. et al., Increased cytotoxicity of soluble Fas ligand by fusing isoleucine zipper motif. Biochem. Biophys. Res. Commun. 322, 197-202 (2004).
55. Suzuki, J., Umeda, M., Sims, P. J., & Nagata, S., Calcium-dependent phospholipid scrambling by TMEM16F. Nature 468, 834-838 (2010).
56. Kitamura, T. et al., Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp. Hematol. 31, 1007-1014 (2003).
57. Higuchi, R., Recombinant PCR in PCR protocols: A guide to methods and applications (Academic Press, San Diego, 1990), pp. 177-188.
58. Kontgen, F., Suss, G., Stewart, C., Steinmetz, M., & Bluethmann, H., Targeted disruption of the MHC class II Aa gene in C57BL/6 mice. Int. Immunol. 5, 957-964 (1993).
59. Kanki, H., Suzuki, H., & Itohara, S., High-efficiency CAG-FLPe deleter mice in C57BL/6J background. Exp. Anim. 55, 137-141 (2006).
60. Cattermole, J. A. et al., Isolation of murine fetal thymus cell lines after infection with recombinant retroviruses containing the v-myc and v-Ha-ras oncogenes. J. Immunol. 142, 3746-3753 (1989).
61. Imao, T. & Nagata, S., Apaf-1- and Caspase-8-independent apoptosis. Cell Death Differ, in press (2012).
62. Akagi, T., Sasai, K., & Hanafusa, H., Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. Proc. Natl. Acad. Sci. USA 100, 13567-13572 (2003).
63. Watson, J. D., Morrissey, P. J., Namen, A. E., Conlon, P. J., & Widmer, M. B., Effect of IL-7 on the growth of fetal thymocytes in culture. J. Immunol. 143, 1215-1222 (1989).
64. Watanabe-Fukunaga, R. et al., The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J. Immunol. 148, 1274-1279 (1992).
65. Ogasawara, J. et al., Lethal effect of the anti-Fas antibody in mice. Nature 364, 806-809 (1993).
66. Aoki, Y., Uenaka, T., Aoki, J., Umeda, M., & Inoue, K., A novel peptide probe for studying the transbilayer movement of phosphatidylethanolamine. J. Biochem. 116, 291-297 (1994).
67. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., & Baylin, S. B., Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821-9826 (1996).
配列番号8:合成プライマー
配列番号9:合成プライマー
配列番号10:合成プライマー
配列番号11:合成プライマー
配列番号12:合成プライマー
配列番号13:合成プライマー
配列番号14:合成プライマー
配列番号15:合成プライマー
配列番号16:shRNAの標的配列
配列番号17:合成プライマー
配列番号18:合成プライマー
配列番号19:合成プライマー
配列番号20:合成プライマー
配列番号21:合成プライマー
配列番号22:合成プライマー
配列番号23:合成プライマー
配列番号24:合成プライマー
配列番号25:合成プライマー
配列番号26:合成プライマー
配列番号27:合成プライマー
配列番号28:合成プライマー
配列番号29:合成プライマー
Claims (9)
- Xkr8の機能を調節する物質のスクリーニング方法であって、以下の工程を含む方法:
(1)Xkr8発現細胞と、Xkr8の機能を調節する物質の候補物質とを接触させる工程、および
(2)該細胞の細胞膜におけるリン脂質の分布を変化させる候補物質を選択する工程。 - リン脂質が、ホスファチジルセリン、ホスファチジルエタノールアミン、ホスファチジルコリン、およびスフィンゴミエリンから選択される、請求項1記載の方法。
- ホスファチジルセリンの細胞膜外葉における分布を増加させる候補物質がXkr8の機能を亢進する物質として選択され、ホスファチジルセリンの細胞膜外葉における分布を減少させる候補物質がXkr8の機能を抑制する物質として選択される、請求項2記載の方法。
- ホスファチジルエタノールアミンの細胞膜外葉における分布を増加させる候補物質がXkr8の機能を亢進する物質として選択され、ホスファチジルエタノールアミンの細胞膜外葉における分布を減少させる候補物質がXkr8の機能を抑制する物質として選択される、請求項2記載の方法。
- ホスファチジルコリンの細胞膜内葉における分布を増加させる候補物質がXkr8の機能を亢進する物質として選択され、ホスファチジルコリンの細胞膜内葉における分布を減少させる候補物質がXkr8の機能を抑制する物質として選択される、請求項2記載の方法。
- スフィンゴミエリンの細胞膜内葉における分布を増加させる候補物質がXkr8の機能を亢進する物質として選択され、スフィンゴミエリンの細胞膜内葉における分布を減少させる候補物質がXkr8の機能を抑制する物質として選択される、請求項2記載の方法。
- アポトーシスが関与する疾患の治療または予防のための薬剤のスクリーニング方法である、請求項1~6のいずれかに記載の方法。
- アポトーシスが関与する疾患が自己免疫疾患である、請求項7記載の方法。
- アポトーシスが関与する疾患ががんである、請求項7記載の方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014547004A JP6229954B2 (ja) | 2012-11-14 | 2013-11-13 | Xkr8の機能を調節する物質のスクリーニング方法 |
US14/440,968 US9857357B2 (en) | 2012-11-14 | 2013-11-13 | Method of screening modulator of XKR8 |
EP13854768.2A EP2921854B1 (en) | 2012-11-14 | 2013-11-13 | Method for screening substance controlling function of xkr8 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261726147P | 2012-11-14 | 2012-11-14 | |
US61/726,147 | 2012-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014077279A1 true WO2014077279A1 (ja) | 2014-05-22 |
Family
ID=50731190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2013/080692 WO2014077279A1 (ja) | 2012-11-14 | 2013-11-13 | Xkr8の機能を調節する物質のスクリーニング方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9857357B2 (ja) |
EP (1) | EP2921854B1 (ja) |
JP (1) | JP6229954B2 (ja) |
WO (1) | WO2014077279A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10295528B2 (en) | 2014-04-08 | 2019-05-21 | Kyoto University | Method of screening ATP11C or CDC50A inhibitor |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022020311A1 (en) * | 2020-07-23 | 2022-01-27 | Tscan Therapeutics, Inc. | Compositions and methods for identifying epitopes |
WO2023136868A1 (en) * | 2022-01-14 | 2023-07-20 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Targeting of xkr8 in therapies |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012029855A1 (ja) | 2010-09-01 | 2012-03-08 | 国立大学法人京都大学 | 血液凝固調節物質のスクリーニング方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204035B1 (en) * | 1996-04-02 | 2001-03-20 | The Blood Center Research Foundation | Methods and compositions to alter the cell surface expression of phosphatidylserine and other clot-promoting plasma membrane phospholipids |
EP1601382A4 (en) * | 2003-03-13 | 2006-11-22 | Univ Utah Res Found | PHOSPHOLIPID SCRAMBLASE 3 |
-
2013
- 2013-11-13 WO PCT/JP2013/080692 patent/WO2014077279A1/ja active Application Filing
- 2013-11-13 EP EP13854768.2A patent/EP2921854B1/en active Active
- 2013-11-13 US US14/440,968 patent/US9857357B2/en active Active
- 2013-11-13 JP JP2014547004A patent/JP6229954B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012029855A1 (ja) | 2010-09-01 | 2012-03-08 | 国立大学法人京都大学 | 血液凝固調節物質のスクリーニング方法 |
Non-Patent Citations (68)
Title |
---|
"Molecular Cloning: A Laboratory Manual", COLD SPRING HARBOR LABORATORY PRESS |
AKAGI, T.; SASAI, K.; HANAFUSA, H.: "Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation", PROC. NATL. ACAD. SCI. USA, vol. 100, 2003, pages 13567 - 13572 |
AOKI, Y.; UENAKA, T.; AOKI, J.; UMEDA, M.; INOUE, K.: "A novel peptide probe for studying the transbilayer movement of phosphatidylethanolamine", J. BIOCHEM, vol. 116, 1994, pages 291 - 297, XP009114004 |
BALASUBRAMANIAN, K.; SCHROIT, A.: "Aminophospholipid asymmetry: A matter of life and death", ANNU. REV. PHYSIOL, vol. 65, 2003, pages 701 - 734 |
BARLOWE, C.: "Signals for COPII-dependent export from the ER: what's the ticket out?", TRENDS CELL BIOL., vol. 13, 2003, pages 295 - 300 |
BEVERS, E.; WILLIAMSON, P.: "Phospholipid scramblase: an update", FEBS LETT, vol. 584, 2010, pages 2724 - 2730 |
BRATTON, D. ET AL.: "Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase", J. BIOL. CHEM., vol. 272, 1997, pages 26159 - 26165 |
CALENDA GIULIA ET AL.: "IDENTIFICATION OF TWO NEW MEMBERS, XPLAC AND XTES OF THE XK FAMILY", GENE, vol. 370, 20 January 2006 (2006-01-20), pages 6 - 16, XP029181756 * |
CALENDA, G. ET AL.: "Identification of two new members, XPLAC and XTES, of the XK family", GENE, vol. 370, 2006, pages 6 - 16, XP026933095, DOI: doi:10.1016/j.gene.2005.10.037 |
CATTERMOLE, J. A. ET AL.: "Isolation of murine fetal thymus cell lines after infection with recombinant retroviruses containing the v-myc and v-Ha-ras oncogenes", J. IMMUNOL., vol. 142, 1989, pages 3746 - 3753 |
CHEKENI, F. B. ET AL.: "Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis", NATURE, vol. 467, 2010, pages 863 - 867 |
COLEMAN, M. ET AL.: "Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I", NAT. CELL BIOL., vol. 3, 2001, pages 339 - 345 |
CONNOR, J.; PAK, C. C.; SCHROIT, A. J.: "Exposure of phosphatidylserine in the outer leaflet of human red blood cells. Relationship to cell density, cell age, and clearance by mononuclear cells", J. BIOL. CHEM., vol. 269, 1994, pages 2399 - 2404 |
ELLIS, R. E.; JACOBSON, D. M.; HORVITZ, H. R.: "Genes required for the engulfment of cell corpses during programmed cell death in Caenorhabditis elegans", GENETICS, vol. 129, 1991, pages 79 - 94, XP002105767 |
EMOTO, K.; TOYAMA-SORIMACHI, N.; KARASUYAMA, H.; INOUE, K.; UMEDA, M.: "Exposure of phosphatidylethanolamine on the surface of apoptotic cells", EXP. CELL RES, vol. 232, 1997, pages 430 - 434, XP002566339, DOI: doi:10.1006/excr.1997.3521 |
ENARI, M. ET AL.: "A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD", NATURE, vol. 391, 1998, pages 43 - 50, XP002089488, DOI: doi:10.1038/34112 |
FADEEL, B. ET AL.: "hosphatidylserine exposure during apoptosis is a cell-type-specific event and does not correlate with plasma membrane phospholipid scramblase expression", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 266, 1999, pages 504 - 511 |
FADEEL, B.; ORRENIUS, S.: "Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease", J. INTER. MED, vol. 258, 2005, pages 479 - 517 |
FADOK, V. A. ET AL.: "Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages", J. IMMUNOL., vol. 148, 1992, pages 2207 - 2216, XP000652154 |
FADOK, V. A.; DE CATHELINEAU, A.; DALEKE, D. L.; HENSON, P. M.; BRATTON, D. L.: "Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts", J. BIOL. CHEM., vol. 276, 2001, pages 1071 - 1077 |
FRANKS, A. L.; SLANSKY, J. E.: "Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer", ANTICANCER RES, vol. 32, 2012, pages 1119 - 1136 |
FUKUNAGA, R.; ISHIZAKA-IKEDA, E.; NAGATA, S.: "Purification and characterization of the receptor for murine granulocyte colony-stimulating factor", J. BIOL. CHEM., vol. 265, 1990, pages 14008 - 14015, XP000909560 |
GADELLA, B.; HARRISON, R.: "Capacitation induces cyclic adenosine 3',5'-monophosphate-dependent, but apoptosis-unrelated, exposure of aminophospholipids at the apical head plasma membrane of boar sperm cells", BIOL. REPROD., vol. 67, 2002, pages 340 - 350 |
GIRAUDO, C. G.; MACCIONI, H. J. F.: "Endoplasmic reticulum export of glycosyltransferases depends on interaction of a cytoplasmic dibasic motif with Sar1", MOL. BIOL. CELL, vol. 14, 2003, pages 3753 - 3766 |
GLEISS, B.; GOGVADZE, V.; ORRENIUS, S.; FADEEL, B.: "Fas-triggered phosphatidylserine exposure is modulated by intracellular ATP", FEBS LETT., vol. 519, 2002, pages 153 - 158, XP004356838, DOI: doi:10.1016/S0014-5793(02)02743-6 |
HAMPTON, M.; VANAGS, D.; PORN-ARES, M.; ORRENIUS, S.: "Involvement of extracellular calcium in phosphatidylserine exposure during apoptosis", FEBS LETT., vol. 399, 1996, pages 277 - 282 |
HERMAN, J. G.; GRAFF, J. R.; MYOHANEN, S.; NELKIN, B. D.; BAYLIN, S. B.: "Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands", PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 9821 - 9826, XP002542477, DOI: doi:10.1073/pnas.93.18.9821 |
HIGUCHI, R.: "Recombinant PCR in PCR protocols: A guide to methods and applications", 1990, ACADEMIC PRESS, pages: 177 - 188 |
HO, M. ET AL.: "Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein", CELL, vol. 77, 1994, pages 869 - 880, XP024244780, DOI: doi:10.1016/0092-8674(94)90136-8 |
IMAO, T.; NAGATA, S.: "Apaf-1- and Caspase-8-independent apoptosis", CELL DEATH DIFFER, 2012 |
JACOBSON, M. D.; WEIL, M.; RAFF, M. C.: "Programmed cell death in animal development", CELL, vol. 88, 1997, pages 347 - 354 |
KANKI, H.; SUZUKI, H.; ITOHARA, S.: "High-efficiency CAG-FLPe deleter mice in C57BL/6J background", EXP. ANIM, vol. 55, 2006, pages 137 - 141 |
KITAMURA, T. ET AL.: "Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics.", EXP. HEMATOL., vol. 31, 2003, pages 1007 - 1014, XP009118675, DOI: doi:10.1016/j.exphem.2003.07.005 |
KONTGEN, F.; SUSS, G.; STEWART, C.; STEINMETZ, M.; BLUETHMANN, H.: "Targeted disruption of the MHC class II Aa gene in C57BL/6 mice", INT. IMMUNO, vol. 5, 1993, pages 957 - 964, XP009169967, DOI: doi:10.1093/intimm/5.8.957 |
LEVENTIS, P. A.; GRINSTEIN, S.: "The Distribution and Function of Phosphatidylserine in Cellular Membranes", ANNU. REV. BIOPHYS, vol. 39, 2010, pages 407 - 427 |
MARGUET, D.; LUCIANI, M. F.; MOYNAULT, A.; WILLIAMSON, P.; CHIMINI, G.: "Engulfment of apoptotic cells involves the redistribution of membrane phosphatidylserine on phagocyte and prey", NAT. CELL BIOL., vol. 1, 1999, pages 454 - 456 |
MARINO GUILLERMO ET AL.: "MECHANISMS OF APOPTOTIC PHOSPHATIDYLSERINE EXPOSURE.", CELL RESEARCH, vol. 23, no. 11, 27 August 2013 (2013-08-27), pages 1247 - 1248, XP055247307 * |
MARTIN, S. J.; FINUCANE, D. M.; AMARANTE-MENDES, G. P.; O'BRIEN, G. A.; GREEN, D. R.: "Phosphatidylserine externalization during CD95-induced apoptosis of cells and cytoplasts requires ICE/CED-3 protease activity", J. BIOL. CHEM., vol. 271, 1996, pages 28753 - 28756 |
MORITA, S.; KOJIMA, T.; KITAMURA, T.: "Plat-E: an efficient and stable system for transient packaging of retroviruses", GENE THER, vol. 7, 2000, pages 1063 - 1066, XP002932672, DOI: doi:10.1038/sj.gt.3301206 |
MUNOZ, L. E.; LAUBER, K.; SCHILLER, M.; MANFREDI, A. A.; HERRMANN, M.: "The role of defective clearance of apoptotic cells in systemic autoimmunity", NAT. REV. RHEUMATOL, vol. 6, 2010, pages 280 - 289 |
NAGATA, S.: "Apoptosis by death factor", CELL, vol. 88, 1997, pages 355 - 365 |
NAGATA, S.: "DNA degradation in development and programmed cell death", ANNU. REV. IMMUNOL., vol. 23, 2005, pages 853 - 875 |
NAGATA, S.; HANAYAMA, R.; KAWANE, K.: "Autoimmunity and the clearance of dead cells", CELL, vol. 140, 2010, pages 619 - 630 |
OGASAWARA, J. ET AL.: "Lethal effect of the anti-Fas antibody in mice", NATURE, vol. 364, 1993, pages 806 - 809, XP001026419, DOI: doi:10.1038/364806a0 |
PALACIOS, R.; STEINMETZ, M.: "Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo", CELL, vol. 41, 1985, pages 727 - 734, XP023913291, DOI: doi:10.1016/S0092-8674(85)80053-2 |
RAVICHANDRAN, K. S.; LORENZ, U.: "Engulfment of apoptotic cells: signals for a good meal", NAT. REV. IMMUNOL, vol. 7, 2007, pages 964 - 974 |
RICCI, J.-E. ET AL.: "Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain", CELL, vol. 117, 2004, pages 773 - 786 |
RUSSO, D.; REDMAN, C.; LEE, S.: "Association of XK and Kell blood group proteins", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, 1998, pages 13950 - 13956 |
SANDILOS, J. K. ET AL.: "Pannexin 1, an ATP Release Channel, Is Activated by Caspase Cleavage of Its Pore-associated C-terminal Autoinhibitory Region", J. BIOL. CHEM., vol. 287, 2012, pages 11303 - 11311 |
SCHOENWAELDER, S. M. ET AL.: "Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function", BLOOD, vol. 114, 2009, pages 663 - 666 |
SEBBAGH, M. ET AL.: "Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing", NAT. CELL BIOL., vol. 3, 2001, pages 346 - 352, XP002280205, DOI: doi:10.1038/35070019 |
SHIRAISHI, T. ET AL.: "Increased cytotoxicity of soluble Fas ligand by fusing isoleucine zipper motif", BIOCHEM. BIOPHYS. RES. COMMUN, vol. 322, 2004, pages 197 - 202, XP004526718, DOI: doi:10.1016/j.bbrc.2004.07.098 |
STANFIELD, G.; HORVITZ, H.: "The ced-8 gene controls the timing of programmed cell deaths in C. elegans", MOL. CELL, vol. 5, 2000, pages 423 - 433 |
STOWELL, S. R. ET AL.: "Galectin-1 induces reversible phosphatidylserine exposure at the plasma membrane", MOL. BIOL. CELL, vol. 20, 2009, pages 1408 - 1418 |
STRASSER, A.; O'CONNOR, L.; DIXIT, V. M.: "Apoptosis signaling", ANNU. REV. BIOCHEM., vol. 69, 2000, pages 217 - 245, XP002283497, DOI: doi:10.1146/annurev.biochem.69.1.217 |
SUZUKI, J.; UMEDA, M.; SIMS, P. J.; NAGATA, S.: "Calcium-dependent phospholipid scrambling by TMEM16F", NATURE, vol. 468, 2010, pages 834 - 838, XP055260744, DOI: doi:10.1038/nature09583 |
SUZUKI, JUN ET AL.: "XK-RELATED PROTEIN 8 AND CED-8 PROMOTE PHOSPHATIDYLSERINE EXPOSURE IN APOPTOTIC CELLS.", SCIENCE, vol. 341, no. 6144, 26 July 2013 (2013-07-26), pages 403 - 406, XP055247304 * |
TIMMER, J. C.; SALVESEN, G. S.: "Caspase substrates", CELL DEATH DIFFER, vol. 14, 2007, pages 66 - 72, XP002516738, DOI: doi:10.1038/SJ.CDD.4402059 |
TUCKER, K. A.; LILLY, M. B.; HECK, L.; RADO, T. A.: "Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity.", BLOOD, vol. 70, 1987, pages 372 - 378, XP009022632 |
VAN DEN EIJNDE, S. ET AL.: "Cell surface exposure of phosphatidylserine during apoptosis is phylogenetically conserved", APOPTOSIS, vol. 3, 1998, pages 9 - 16 |
VAN DEN EIJNDE, S. ET AL.: "Transient expression of phosphatidylserine at cell-cell contact areas is required for myotube formation", J. CELL SCI., vol. 114, 2001, pages 3631 - 3642 |
VAUX, D. L.; KORSMEYER, S. J.: "ell death in development", CELL, vol. 96, 1999, pages 245 - 254 |
VENEGAS, V.; ZHOU, Z.: "Two alternative mechanisms that regulate the presentation of apoptotic cell engulfment signal in Caenorhabditis elegans", MOL. BIOL. CELL, vol. 18, 2007, pages 3180 - 3192, XP055276514, DOI: doi:10.1091/mbc.E07-02-0138 |
WATANABE-FUKUNAGA, R. ET AL.: "The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen", J. IMMUNOL., vol. 148, 1992, pages 1274 - 1279 |
WATSON, J. D.; MORRISSEY, P. J.; NAMEN, A. E.; CONLON, P. J.; WIDMER, M. B.: "Effect of IL-7 on the growth of fetal thymocytes in culture", J. IMMUNOL., vol. 143, 1989, pages 1215 - 1222 |
WILLIAMSON, P. ET AL.: "Phospholipid scramblase activation pathways in lymphocytes", BIOCHEMISTRY, vol. 40, 2001, pages 8065 - 8072 |
YOSHIDA, H. ET AL.: "Phosphatidylserine-dependent engulfment by macrophages of nuclei from erythroid precursor cells", NATURE, vol. 437, 2005, pages 754 - 758 |
ZWAAL, R.; COMFURIUS, P.; BEVERS, E.: "Lipid-protein interactions in blood coagulation", BIOCHIM. BIOPHYS. ACTA, vol. 1376, 1998, pages 433 - 453, XP004281741, DOI: doi:10.1016/S0304-4157(98)00018-5 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10295528B2 (en) | 2014-04-08 | 2019-05-21 | Kyoto University | Method of screening ATP11C or CDC50A inhibitor |
US11073510B2 (en) | 2014-04-08 | 2021-07-27 | Kyoto University | Method of screening ATP11C or CDC50A inhibitor |
US11692999B2 (en) | 2014-04-08 | 2023-07-04 | Kyoto University | Method of screening ATP11C or CDC50A inhibitor |
Also Published As
Publication number | Publication date |
---|---|
JPWO2014077279A1 (ja) | 2017-01-05 |
US9857357B2 (en) | 2018-01-02 |
EP2921854A1 (en) | 2015-09-23 |
EP2921854B1 (en) | 2017-09-13 |
EP2921854A4 (en) | 2016-05-04 |
US20150301024A1 (en) | 2015-10-22 |
JP6229954B2 (ja) | 2017-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rogers et al. | Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation | |
Suzuki et al. | Exposure of phosphatidylserine by Xk-related protein family members during apoptosis | |
Tian et al. | p85α recruitment by the CD300f phosphatidylserine receptor mediates apoptotic cell clearance required for autoimmunity suppression | |
Shin et al. | NOTCH1 can initiate NF-κB activation via cytosolic interactions with components of the T cell signalosome | |
Ryoden et al. | Requirement of Xk and Vps13a for the P2X7-mediated phospholipid scrambling and cell lysis in mouse T cells | |
Barnes et al. | Compartmentalization of photoreceptor sensory cilia | |
Hara et al. | Clustering of CARMA1 through SH3–GUK domain interactions is required for its activation of NF-κB signalling | |
JP6229954B2 (ja) | Xkr8の機能を調節する物質のスクリーニング方法 | |
Inanç et al. | Abnormal centrosomal structure and duplication in Cep135-deficient vertebrate cells | |
Ouellette et al. | Spatial control of active CDC-42 during collective migration of hypodermal cells in Caenorhabditis elegans | |
Ryoden et al. | Functional expression of the P2X7 ATP receptor requires eros | |
Emperador-Melero et al. | Phosphorylation triggers presynaptic phase separation of Liprin-α3 to control active zone structure | |
US11692999B2 (en) | Method of screening ATP11C or CDC50A inhibitor | |
JP5855003B2 (ja) | 血液凝固調節物質のスクリーニング方法 | |
Nguyen et al. | Mitochondrial Bcl-xL promotes brain synaptogenesis by controlling non-lethal caspase activation | |
Geng | Post-translational modifications of the ligands: Requirement for TAM receptor activation | |
EP2839279B1 (en) | Method for screening a modulator of a tmem16 family member | |
WO2023048299A1 (ja) | Xk及び/又はvps13aの利用 | |
JP2006290848A (ja) | T細胞受容体機能調節用組成物及びそのスクリーニング方法 | |
Turotszy | The role of NARF and other novel progeria-associated genes/proteins in ageing processes. | |
領田優太 | Functional expression of the P2X7 ATP receptor | |
Turner et al. | The lysosomal trafficking regulator “LYST”: an 80-year traffic jam | |
JP4982847B2 (ja) | Ganpによる癌抑制遺伝子の活性化方法 | |
JP4843595B2 (ja) | 生体内のアポトーシス細胞の除去促進剤及び除去阻害剤 | |
ES2351646A1 (es) | Mamífero no humano modificado genéticamente, células y métodos para producirlas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13854768 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014547004 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2013854768 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013854768 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14440968 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |